Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
Sign Up to like & getrecommendations! Published in 2022 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-022-00607-x
Abstract: Imipenem/cilastatin/relebactam (IMI/REL), a combination β-lactam antibiotic (imipenem) with a novel β-lactamase inhibitor (relebactam), is an efficacious and well-tolerated option for the treatment of hospitalized patients with gram-negative (GN) bacterial infections caused by carbapenem-non-susceptible (CNS) pathogens.… read more here.
Keywords: imipenem; imi rel; cost; cms imi ... See more keywords